Mediwound (MDWD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and has a $25.00 price target.
Josh Jennings has given his Buy rating due to a combination of factors including the strong momentum in the US rollout of NexoBrid by partner Vericel, evidenced by a significant increase in hospital orders. Mediwound’s recent launch of a Phase III trial for EscharEx in venous leg ulcers (VLU) and plans for further trials indicate a robust pipeline that could drive future growth. The company’s revenue for the fourth quarter met expectations, and although there is currently a manufacturing capacity constraint, this is expected to improve as capacity ramps up throughout the year.
Additionally, Mediwound’s revenue projections for the coming years remain strong, with anticipated growth driven by the launch of NexoBrid in new markets such as the US, Japan, and India, and a new partnership in Europe. The upcoming introduction of a Category III CPT code in the US is expected to further enhance NexoBrid’s adoption, supported by Vericel’s expertise in burn care. These factors collectively contribute to a positive outlook for Mediwound, justifying the Buy rating.
According to TipRanks, Jennings is a 4-star analyst with an average return of 3.6% and a 49.50% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Stereotaxis, Stryker, and Avita Medical.
Questions or Comments about the article? Write to editor@tipranks.com